MULTI-OMIC INTEGRATION OF WGS, WTS, AND MIRNA PROFILES ELUCIDATES THE MOLECULAR BASIS OF CLL HETEROGENEITY

EHA Library, Wencke Walter, 4207573

OUTCOMES AFTER 1L TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BELONGING TO STEREOTYPED SUBSET #2, AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC.

EHA Library, Thomas Chatzikonstantinou, 4207578

SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH TARGETED THERAPIES IN THREE PHASE-III TRIALS OF THE GERMAN CLL STUDY GROUP

EHA Library, Ellinor Goergen, 4207579

DUAL MAPK PATHWAY INHIBITION, ALONE OR COMPLEMENTED BY ANTI-CD20 IMMUNOTHERAPY, IN PREVIOUSLY TREATED HAIRY CELL LEUKEMIA/HCL: A HIGHLY ACTIVE TARGETED STRATEGY OF FIXED AND SHORT DURATION

EHA Library, Alessandro Mancini, 4207585

PERSISTENT UNDETECTABLE MINIMAL RESIDUAL DISEASE AND LONG-TERM REMISSIONS IN PATIENTS WITH CLL AFTER TREATMENT WITH OBINUTUZUMAB-VENETOCLAX

EHA Library, Karen Swart, 4207588

SUBSEQUENT THERAPIES AND TIME TO SECOND PROGRESSION-FREE SURVIVAL EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY TREATED WITH ZANUBRUTINIB OR BENDAMUSTINE-RITUXIMAB

EHA Library, Constantine S. Tam, 4207589

A LONGITUDINAL COMPREHENSIVE GERIATRIC ASSESSMENT TO DEFINE FITNESS IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AGED ≥65 YEARS: A PROSPECTIVE MULTICENTER ITALIAN STUDY (CLYF TRIAL)

EHA Library, Anna Maria Frustaci, 4207590

A PRE-TREATMENT PROGNOSTIC SCORE FOR HAIRY CELL LEUKEMIA TREATED WITH 2CDA: DEVELOPMENT AND INTERNAL VALIDATION IN A MULTICENTRIC COHORT OF 513 PATIENTS

EHA Library, Francesco Angotzi, 4207591

LONG-TERM FOLLOW-UP RESULTS OF A PHASE 2 STUDY OF VENETOCLAX ADDED TO IBRUTINIB TO ELIMINATE RESISTANCE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Kerry Rogers, 4207592

TREATMENT BURDEN AMONG PATIENTS (PTS) AGED 75 OR OLDER WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

EHA Library, Daniel Ermann, 4207593

SAFETY AND EFFICACY OF DOSE-MODIFIED APPROACHES OF FIXED-DURATION (FD) IBRUTINIB+VENETOCLAX (I+V) IN PATIENTS WITH PREVIOUSLY UNTREATED CLL: PRIMARY ANALYSIS OF THE PROSPECTIVE PHASE 2 TAILOR STUDY

EHA Library, Paolo Ghia, 4207594

FEASIBILITY AND SAFETY OF VENETOCLAX–OBINUTUZUMAB IN FIT AND UNFIT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: COMPARISON OF CLL13 AND CLL14 POOLED ANALYSIS WITH AN ITALIAN CLINICAL PRACTICE COHORT

EHA Library, Arianna Zappaterra, 4207595

REAL-LIFE DATA ON FIRST LINE AND RELAPSED/REFRACTORY CLL ACALABRUTINIB TREATMENT: UPDATED 3Y RESULTS OF THE LARGE NAOS OBSERVATIONAL STUDY IN FRANCE, INCLUDING HIGH-RISK AND IBRUTINIB-EXPOSED PATIENTS

EHA Library, Anne Quinquenel, 4207597

DURABLE RESPONSES AFTER TIME-LIMITED THERAPY WITH ZANUBRUTINIB PLUS RITUXIMAB IN PATIENTS WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jan Burger, 4207600

SAFETY OF FIXED-DURATION (FD) ACALABRUTINIB-VENETOCLAX COMBINATIONS IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) STRATIFIED BY AGE: POST HOC ANALYSIS OF THE PHASE 3 AMPLIFY TRIAL

EHA Library, J.F. Seymour, 4207602

EFFECT OF A STRUCTURED, SEMI-SUPERVISED EXERCISE INTERVENTION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FITNESS, CLINICAL OUTCOMES, AND CIRCULATING IMMUNE REPERTOIRE

EHA Library, McKayla Deisz*, 4207603

REAL-WORLD ZANUBRUTINIB TREATMENT PATTERNS IN CLL/SLL AMONG US COMMUNITY ONCOLOGY PATIENTS WITH PRIOR ACALABRUTINIB THERAPY

EHA Library, Rushir Choksi, 4207606

EARLY PREDICTION OF NILOTINIB RESPONSE IN CHRONIC MYELOID LEUKEMIA BY DRUG PLASMA CONCENTRATION AND SINGLE-CELL SIGNALING PROFILING

EHA Library, Stein-Erik Gullaksen, 4207608

PERIPHERAL BLOOD NEUTROPHIL QUANTITY AND MATURATION PREDICT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Tatsuya Mihashi, 4207612

PROGNOSTIC IMPACT OF ADDITIONAL SOMATIC MUTATIONS ON TKD DEVELOPMENT, MOLECULAR RESPONSE AND SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS

EHA Library, Ruth Stuckey, 4207615

EFFICACY AND SAFETY OF PONATINIB IN PEDIATRIC PATIENTS WITH BCR::ABL–POSITIVE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML): PRELIMINARY RESULTS FROM THE INCB84344-102 STUDY

EHA Library, Franco Locatelli, 4207616

ASCIMINIB VERSUS SECOND-GENERATION TKIS IN CHRONIC-PHASE CML AFTER ≥2 PRIOR TKIS: A PROPENSITY SCORE-MATCHED ANALYSIS

EHA Library, Noora Obaidallah, 4207620

ASCIMINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INTERIM RESULTS FROM A PHASE II TRIAL

EHA Library, Elias Jabbour, 4207623

TYROSINE KINASE INHIBITOR USE AND THE RISK OF NEURODEGENERATIVE DISEASE: A SWEDISH POPULATION-BASED COHORT STUDY

EHA Library, Felix Wittström, 4207624

IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ON CLINICAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA IN BLAST PHASE

EHA Library, Rikki Williams, 4207625

THERAPEUTIC SILENCING OF TMPRSS6 ATTENUATES IRON-DRIVEN INFLAMMASOME ACTIVATION AND DELAYS DISEASE PROGRESSION IN MDS MICE

EHA Library, Jim Vadolas, 4207630

REFINING MDS CLASSIFICATION: CHARACTERIZATION OF NOVEL STAG2, EZH2, -7, AND TET2 BI-ALLELIC ENTITIES AND THEIR IMPACT ON RISK STRATIFICATION

EHA Library, Carlos Ruiz Arenas, 4207631

MAPPING AZACITIDINE RESPONSE IN VEXAS WITH PAIRED SINGLE-CELL TRANSCRIPTOMICS AND PLASMA PROTEOMICS

EHA Library, Lourdes Mendez, 4207636

DIVERGENT ROLES OF STAT3 AND STAT5 IN LEUKEMIC TRANSFORMATION

EHA Library, Eleni Katsantoni, 4207637

CLK INHIBITOR CTX-712 POTENTIATES THE ACTIVITY OF ABT-199 AND AZACYTIDINE IN MYELOID LEUKEMIA

EHA Library, Guillermo Garcia-Manero, 4207639

INCREASED MITOCHONDRIAL ACTIVITY IN HSPCS AND MONOCYTES/MACROPHAGES COMPARTMENT REVEALS METABOLIC VULNERABILITIES IN MYELODYSPLASTIC SYNDROMES

EHA Library, Manuela Albuquerque de Melo, 4207642

USP15 ALTERNATIVE SPLICING MAY GUIDE TGF-B PATHWAY HYPERACTIVATION IN SF3B1-K700E LOWER RISK MYELODYSPLASTIC SYNDROMES IMPAIRING ERYTHROPOIESIS.

EHA Library, Emiliano Fabiani, 4207643

WHOLE GENOME SEQUENCING REVEALS NOVEL, CLINICALLY RELEVANT BIOMARKER MISSED BY STANDARD OF CARE FOR PATIENTS WITHIN MYELODYSPLASTIC SYNDROME

EHA Library, Alex Bataller, 4207644

MOLECULAR PREDICTORS OF CLINICAL EFFICACY WITH VENETOCLAX AND HYPOMETHYLATING AGENT IN THE FRONTLINE MANAGEMENT OF HIGHER RISK MYELODYSPLASTIC SYNDROME

EHA Library, Guru Subramanian Guru Murthy, 4207648

CYTO-CMML: A MUTATION-INDEPENDENT CYTOGENETIC RISK CLASSIFIER FOR CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Matteo Giovanni Della Porta, 4207650

TRANSLATIONAL INSIGHTS AND CLINICAL EFFICACY WITH BEXMARILIMAB AND AZACITIDINE IN HR-MDS IN THE BEXMAB PHASE 1/2 STUDY

EHA Library, Mika Kontro, 4207651

VALIDATION OF MOLECULAR PROGNOSTIC MODELS FOR CHRONIC MYELOMONOCYTIC LEUKEMIA IN A LARGE MULTICENTER COHORT

EHA Library, Lara Gonzalez Palenzuela, 4207653

IMPACT OF U2AF1 PATHOGENIC VARIANTS ON PROGNOSIS OF MYELODYSPLASTIC NEOPLASMS WITH RUNX1 MUTATION

EHA Library, Linlin Liu, 4207654

OUTCOMES AND CHARACTERISTICS OF LOWER-RISK MDS PATIENTS WITH ELEVATED SERUM ERYTHROPOIETIN LEVELS (≥500 IU/L): A MULTICENTER STUDY BY THE POLISH ADULT LEUKEMIA GROUP (PALG)

EHA Library, Piotr Stompór, 4207657

REAL-WORLD OUTCOMES OF IMETELSTAT: INTERROGATING SAFETY, EFFICACY AND PREDICTORS OF RESPONSE IN HEAVILY PRETREATED LOWER-RISK MDS PATIENTS

EHA Library, Rami S. Komrokji, 4207658

POOLED PHASE1/2 DATA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND MDS/MYELOPROLIFERATIVE NEOPLASMS SUPPORTS A BODY SURFACE AREA (BSA)-BASED DOSING STRATEGY FOR ORAL AZACITIDINE-CEDAZURIDINE

EHA Library, Guillermo Garcia-Manero, 4207659

PHASE I STUDY OF OP-2100, AN ORALLY BIOAVAILABLE PRODRUG OF DECITABINE, FOR PATIENTS WITH RELAPSED OR REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Senji Kasahara, 4207660

A NEW ORAL DOSAGE FORM OF DECITABINE/CEDAZURIDINE DEMONSTRATED CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN MYELODYSPLASTIC SYNDROMES PATIENTS IN CHINA: FIRST RESULTS FROM A PIVOTAL TRIAL

EHA Library, Xinping Zhou, 4207661

HEAVY METAL ABNORMALITIES IN UNEXPLAINED CYTOPENIAS AND LOW‑BLAST MYELODYSPLASTIC NEOPLASMS: A PROSPECTIVE INTERVENTIONAL COHORT STUDY FROM NORTH INDIA

EHA Library, kartikey saini, 4207663

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF LUSPATERCEPT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) IN CHINA (‘REACH’ STUDY)

EHA Library, Zhijian Xiao, 4207664

BLAST DEMONSTRATES HIGHER PROGNOSTIC ACCURACY FOR SURVIVAL THAN CPSS IN CHINESE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Zheng Ge, 4207665

TARGETING ASH1L-STING AXIS RESTORES NK CELL FUNCTION AND AMELIORATES IMMUNE-MEDIATED BONE MARROW FAILURE DISEASES

EHA Library, Nan Song, 4207667

MODELING PNH EVOLUTION: GENETIC DRIFT AND CLINICAL DETERMINANTS

EHA Library, Ramkarthic Ramanathan, 4207668

PREVALENCE AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MULTICENTER STUDY.

EHA Library, Nicole Galli, 4207672

THE CROSSROADS BETWEEN BONE MARROW STEM CELL DEFECTS AND IMMUNE DYSREGULATION IN ADENOSINE DEAMINASE 2 DEFICIENCY: IMPLICATIONS FOR MONITORING AND HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Federica Barzaghi, 4207674

MULTIOMIC ANALYSIS OF NORMAL B CELLS IN CLL AND IBRUTINIB-TREATED PATIENTS DEMONSTRATES OLIGOCLONALITY, REDUCED POTENTIAL FOR T CELL INTERACTION AND GC FORMATION, AND BTK BYPASS USING PI3K AND NF-KB

EHA Library, Amelia Fisher, 4207575

THE IMPACT OF FIRST-LINE THERAPY ON T CELL FITNESS IN CHRONIC LYMPHATIC LEUKEMIA

EHA Library, Giulia Benintende, 4207576

SESHAT II AND THE NEW UMD TP53 ERA: TURNING NOISY TP53 SEQUENCING INTO CLEAN, CLINICALLY ACTIONABLE REPORTS.

EHA Library, Thierry Soussi, 4207577

FIGHT TRIAL: FIXED-DURATION IBRUTINIB PLUS OBINUTUZUMAB AS FIRST-LINE THERAPY FOR TP53-INTACT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Emanuela Sant'Antonio, 4207580

VENETOCLAX AND DELAYED RITUXIMAB WITH IBRUTINIB CONSOLIDATION AIMING AT UNDETECTABLE MINIMAL RESIDUAL DISEASE IN TREATMENT-NAÏVE (TN) PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): VALUABLE TRIAL

EHA Library, Francesca Martini, 4207582

THE CLINICAL AND BIOLOGICAL CHARACTERISTICS AND OUTCOMES OF ACCELERATED CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTER TRANSFORMATION

EHA Library, Huayuan Zhu, 4207583

IMPACT OF SEX ON EFFICACY, TOLERABILITY AND PATIENT-REPORTED OUTCOMES IN FIRST-LINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE CLL13/GAIA STUDY

EHA Library, Julia von Tresckow, 4207584

FINAL RESULTS FROM ASSURE: A PHASE 3B STUDY OF THE SAFETY AND EFFICACY OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Stephen Opat, 4207586

PRIMARY ENDPOINT ANALYSIS OF A PHASE II STUDY USING MINIMAL RESIDUAL DISEASE STATUS TO GUIDE VENETOCLAX DURATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Meghan C. Thompson, 4207587

REAL-WORLD TREATMENT AND SURVIVAL OUTCOMES FOR ZANUBRUTINIB AND ACALABRUTINIB MONOTHERAPY AMONG TREATMENT-NAÏVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES

EHA Library, Ryan Jacobs, 4207596

ORELABRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: SAFETY AND EFFICACY RESULTS FROM A GLOBAL PHASE 1/2 STUDY

EHA Library, Yucai Wang, 4207598

REAL-WORLD OUTCOMES IN PATIENTS WITH CLL TREATED WITH FIRST-LINE IBRUTINIB OR ACALABRUTINIB AND UNDERGOING DOSE REDUCTIONS: A CHART REVIEW STUDY

EHA Library, Mazyar Shadman, 4207599

REAL-WORLD FIRST-LINE FIXED-DURATION (FD) IBRUTINIB+VENETOCLAX (IBR+VEN) TREATMENT (TX) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ANALYSIS FROM THE PROSPECTIVE REALITY-WW STUDY

EHA Library, Catherine Thieblemont, 4207601

IMPACT OF IGHV MUTATIONAL STATUS ON OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Christof Schneider, 4207604

FIXED‑DURATION IBRUTINIB PLUS VENETOCLAX IN FRONTLINE CLL/SLL: UPDATED REAL‑WORLD OUTCOMES FROM THE SPANISH LI+VE STUDY

EHA Library, JOSE ANGEL HERNANDEZ RIVAS, 4207605

AUTOIMMUNE COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA – A SINGLE INSTITUTION STUDY OVER 30 YEARS

EHA Library, Stephen Mulligan, 4207607

EMERGENCE OF HIGHLY ASCIMINIB-RESISTANT CML VIA MINOR BCR::ABL1 SWITCH AND MUTATIONS

EHA Library, Barbora Štefíková, 4207609

FUNCTIONAL DETECTION OF TKI RESISTANCE IN LIVING CML CELLS USING THE FRET BIOSENSOR PICKLES

EHA Library, Tatsuaki MIZUTANI, 4207610

TARGETING EPIGENETIC–METABOLIC CROSSTALK IN CML VIA BUTYRATE-INDUCED HDAC INHIBITION

EHA Library, Rita Vacca, 4207611

FRONTLINE ASCIMINIB FOR CHRONIC PHASE CML: LONG TERM SAFETY AND EFFICACY IN THE ALLG CM13 ASCEND TRIAL

EHA Library, David Yeung, 4207613

GENOMIC AND TRANSCRIPTOMIC FEATURES OF TRANSFORMED CHRONIC MYELOID LEUKEMIA IN BLAST PHASE

EHA Library, Mei Bao, 4207614

LONG-TERM OUTCOMES OF VERY LOW-DOSE DASATINIB IN OLDER PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA: EXTENDED FOLLOW-UP OF THE DAVLEC PHASE 2 TRIAL

EHA Library, Kazunori Murai, 4207617

THE SAFETY, TOLERABILITY, AND EFFICACY OF HS-10382 COMBINED WITH FLUMATINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CML: A PHASE 1B STUDY

EHA Library, Yu Hu, 4207618

PHASE II TRIAL OF DASATINIB IN COMBINATION WITH ASTX727 IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA

EHA Library, Elias Jabbour, 4207619

TWO-YEAR OUTCOMES OF LOW-DOSE VERSUS STANDARD-DOSE DASATINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKAEMIA: A RETROSPECTIVE ANALYSIS

EHA Library, Shailendra Verma, 4207621

HIGHER FIRST LINE TKI RESISTANCE IN ADOLESCENTS AND YOUNG ADULTS (AYA) WITH CHRONIC MYELOID LEUKEMIA. EVIDENCE FROM A POPULATION-BASED REGISTRY.

EHA Library, Maria Jose Herranz Marti, 4207622

A SINGLE-CENTER, CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF HS-10382 IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP)

EHA Library, Li Zhou, 4207626

EFFICACY AND SAFETY OF REDUCED-DOSE DASATINIB (50 MG/DAY) AS FIRST-LINE THERAPY IN CHRONIC MYELOID LEUKEMIA: RESULTS FROM A MULTICENTER REAL-WORLD STUDY BY THE SPANISH CML GROUP

EHA Library, Maria Raquel De Paz Arias, 4207627

LOSS OF HNRNPK DRIVES CMML THROUGH ABERRANT NF1 SPLICING AND RAS ACTIVATION

EHA Library, Miguel Angel Marugal, 4207628

RNA-GUIDED SELECTIVE DNMT1 INHIBITION RESTORES MYELOID DIFFERENTIATION AND OUTPERFORMS AZACITIDINE IN TET2-MUTANT MYELODYSPLASTIC SYNDROMES

EHA Library, Annalisa Di Ruscio, 4207629

RETROTRANSPOSABLE ELEMENT DEREPRESSION DISTINGUISHES DNMT3A- FROM TET2-MUTANT CLONAL HEMATOPOIESIS

EHA Library, Mohammad M Karimi, 4207632

TET2 MUTATION IS ASSOCIATED WITH FAVORABLE PROGNOSIS AND SPECIFIC EPIGENETIC CHROMATIN STATE SHIFTS IN CMML

EHA Library, Matilda Kjellander Kynning, 4207633

MUTANT SHP2 CONDENSATES IMPAIR MICROTUBULE FUNCTION VIA PAK1 RECRUITMENT TO FOSTER GENOMIC INSTABILITY IN JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Chunmou Li, 4207634

YOUNG AGE AT DIAGNOSIS OF A MYELOID NEOPLASIA AS A STANDALONE CRITERION FOR GERMLINE INVESTIGATION: RESULTS FROM A PROSPECTIVE COHORT STUDY

EHA Library, Panagiotis Baliakas, 4207635

LANDSCAPE OF METABOLIC DYSREGULATION WITHIN THE MYELODYSPLASTIC BONE MARROW MICROENVIRONMENT.

EHA Library, Aikaterini Poulaki, 4207638

DEFINING THE ERYTHROBLASTIC ISLAND MACROPHAGE AND ITS INVOLVEMENT IN THE PATHOGENESIS AND ANEMIC STATE OF LOW-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Sadaf Fazeli, 4207641

LARGE-SCALE MULTI-PHENOTYPE WHOLE SLIDE IMAGING ANALYSIS UNCOVERS SPATIAL NICHE ARCHETYPES ALONG THE MDS/AML CONTINUUM

EHA Library, Mischa Selig, 4207645

IMMUNE AND NICHE-ASSOCIATED TRANSCRIPTIONAL REMODELING ACROSS MDS AND AML AND ITS RELATIONSHIP TO RECURRENT GENETIC ALTERATIONS

EHA Library, Seon Young Kim, 4207646

UPDATED OVERALL SURVIVAL AND LONG-TERM TRANSFUSION INDEPENDENCE IN ESA-NAIVE PATIENTS WITH LOWER-RISK MDS: RESULTS FROM THE PHASE 3 COMMANDS TRIAL

EHA Library, Valeria Santini, 4207647

WHICH PATIENTS WITH MDS-H AND MDS-LB BENEFIT FROM ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION? EVIDENCE FROM A LARGE SINGLE-CENTER RETROSPECTIVE COHORT OF 636 PATIENTS

EHA Library, Wenjing Guo, 4207649

CARDIOVASCULAR OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A NATIONWIDE POPULATION-BASED COHORT STUDY IN TAIWAN

EHA Library, Sin-Syue Li, 4207652

ROXADUSTAT IMPROVES TRANSFUSION INDEPENDENCE IN LR-MDS PATIENTS WITH ANEMIA AND HIGH TRANSFUSION BURDEN AND IN RING SIDEROBLAST POSITIVE AND NEGATIVE DISEASE: POST-HOC ANALYSIS OF MATTERHORN STUDY

EHA Library, Amer M. Zeidan, 4207656

BEYOND STATIC BASELINES: PREDICTIVE VALUE OF DYNAMIC KARYOTYPE EVOLUTION FOR DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN MYELODYSPLASTIC NEOPLASMS

EHA Library, Zheng Ge, 4207662

INTEGRIN Α9 (ITGA9): CLINICAL CORRELATION AND MOLECULAR MECHANISM IN MYELODYSPLASTIC SYNDROMES

EHA Library, Xuanlu Wu, 4207666

JDP2-AS1 DRIVES STAT5B-DEPENDENT HDAC11 TRANSCRIPTION TO PROMOTE CD8+ T-CELL HYPERACTIVATION IN APLASTIC ANEMIA

EHA Library, Ling Deng, 4207669

EARLY INFLAMMATORY REPROGRAMMING OF PRIMITIVE HEMATOPOIETIC STEM CELLS DRIVES BONE MARROW FAILURE IN ADENOSINE DEAMINASE 2 DEFICIENCY

EHA Library, Chiara Rigamonti, 4207670

UMBILICAL CORD MESENCHYMAL STEM CELLS IN COMBINATION WITH FIRST-LINE IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA: IMPACT ON EARLY INFECTIOUS COMPLICATIONS AND HEMATOLOGIC RESPONSE DEPTH

EHA Library, Jingnan Sun, 4207671

RESTORATION OF RPS19 EXPRESSION IN HUMAN CELLULAR MODELS OF DIAMOND-BLACKFAN ANAEMIA SYNDROME

EHA Library, Joan Case, 4207673

EFFICACY AND SAFETY OF HRS-5965 VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED PHASE 3 TRIAL

EHA Library, Bing Han, 4207675

EFFICACY AND SAFETY OF HRS-5965 IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH PERSISTENT ANEMIA DESPITE STABLE C5 INHIBITOR THERAPY: A MULTICENTER, SINGLE-ARM, OPEN-LABEL PHASE 3 STUDY

EHA Library, Meili Ge, 4207676